English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

2 The photo shows the “stent” coated with “biocompatible and bioabsorbable poly (D, L-lactide-co-glycolide) (PLGA) nanoparticles (NPs)” which are known to have advanced DDS functions such as the sustained-release by its hydrolysis property and the intracellular delivery by its small size effect. “Stent” is a medical device formed of metallic meshed tube and used as a measure to treat the stenosis of the artery to improve the blood flow by eternal expanding and supporting of the blood vessels. The use of a bare metal stent (BMS) as the 1 generation device is known to reduce the re-stenosis by 20~30%. The re-stenosis rate was reduced to <10% by drug-eluting stents (DES) developed as the 2 generation, which gradually release a drug substance such as an anticancer or immunosuppressive agent from the polymer layer formed on the stent surface to the blood vessel. However, it became a new major concern that the late stent thrombosis (LST) resulted in higher rate of mortality or myocardial infarction by irritating properties of the polymer layer containing the drugs than BMS from the half year follow-up. Under these circumstances, various kinds of the 3 generation stent have been actively developed. Authors also focus on the development of new stent using PLGA nanoparticles as the 3 generation. The nonirritating drug loaded PLGA NPs coated stent can be expected to drastically restrain the re-stenosis rate by sustained-releasing the drug from the PLGA NPs delivered in inflammatory cells by the disembarrassment as nanoparticles from the surface of the expanded stent.

Development of drug-eluting stent coated with PLGA nanoparticles as drug carriers